ClinicalTrials.gg
CompletedNCT06257017Updated Oct 28, 2026

Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma

A Phase 2 interventional study of gemcitabine and Cisplatin in Muscle Invasive Bladder Urothelial Carcinoma and Muscle-Invasive Bladder Carcinoma, sponsored by Yung NA. Completed at 1 site in Hong Kong. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Yung NA · Phase 2, Interventional, and Treatment

How we know

Updated Oct 28, 2026Now CompletedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Urothelial carcinomas are one of the most commonly diagnosed cancers worldwide. Postoperative patients carry a poor prognosis with an estimated five-year disease-specific survival rate of 50%. To improve overall survival and reduce the recurrent risk, chemotherapy is recommended as a standard of care. However, currently in Hong Kong, neoadjuvant (preoperational) chemotherapy and adjuvant (postoperative) chemotherapy are not commonly or regularly provided due to the concern of the potential harm from both physicians and patients. Recently, genetic signature from circulating tumor DNA (ctDNA) is emerging as a pivotal biomarker for detecting caner in early stage and molecular residual disease (MRD). With strengths of non-invasive and superior sensitivity, ctDNA is hopefully to serve as a cancer-agnostic surrogate analyte for risk stratification of tumor recurrence, thereby guiding individually tailored treatment. Therefore, this study is proposed to exploratively assess the benefit of ctDNA-guided approach for postoperative adjuvant therapy.

02

Conditions studied

  • Muscle Invasive Bladder Urothelial Carcinoma
  • Muscle-Invasive Bladder Carcinoma

Keywords

  • circulating tumor DNA
  • ctDNA
  • molecular residual disease
03

In context

Lead sponsor

Yung NA is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. aged 18-70 years old;
  2. a score of ≤1 for the (ECOG) Performance Status;
  3. receiving radical cystectomy (with lymph node dissection) or nephroureterectomy;
  4. confirmed (surgical specimen) muscle invasive urothelial carcinoma, and the major histological type should be transitional cell carcinoma;
  5. Classification of tumour, node and (TNM): pT2-4a N0-2M0;
  6. absence of microscopic (i.e., positive margin) or gross residual of the tumor (R0 resection) and absence of metastasis, confirmed by a negative CT or MRI scan of pelvis, abdomen and chest within 4 weeks prior to enrolment;
  7. adequate hematologic and end-organ function, defined by the following laboratory results obtained within 28 days prior to the first study treatment:

    • ≥1500 cells/μL (without granulocyte colony-stimulating factor support within 2 weeks prior to Cycle 1, Day 1)
    • WBC counts > 2500 cells/μL
    • Lymphocyte count ≥ 300 cells/μL
    • count ≥ 100,000 cells/μL (without transfusion within 2 weeks prior to Cycle 1, Day 1)
    • ≥ 9.0 g/dL
    • , ALT, and alkaline phosphatase ≤ 2.5 × the (ULN),
    • ≤ 1.5 × ULN
    • PT ≤ 1.5 × ULN or INR \< 1.7
    • Calculated ≥ 30 mL/min (Cockcroft-Gault formula)
  8. able to understand and provide written , and agree to receive the treatment arrangement and study procedures stated in the informed consent

Exclusion criteria

Exclusion Criteria:

  1. receiving any approved anti-cancer treatment within 3 weeks prior to study enrolment;
  2. participation in another clinical trial with therapeutic intent within 28 days prior to enrolment;
  3. suffering from other than urothelial carcinoma within 5 years prior to study enrolment;
  4. conditions that contraindicate chemotherapy, such as renal impairment with rate (CCr) \<50 mL/min, hearing impairment, and inadequate marrow function;
  5. anaphylactic or reactions or other to cisplatin and gemcitabine;
  6. active or uncontrolled infections, including (HIV), virus (HBV), virus (HCV), or tuberculosis;
  7. pregnancy or breastfeeding.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Gemcitabine plus cisplatin chemotherapy arm (GC arm)

    Patients in this group will receive adjuvant chemotherapy of gemcitabine and cisplatin, prior to radiological progression

    Drug: gemcitabine · Drug: Cisplatin

  • Other
    Standard management arm (SM arm)

    Patients in this group will receive chemotherapy of gemcitabine and cisplatin only after radiological progression is observed

    Drug: gemcitabine · Drug: Cisplatin

Interventions

  • 1,000 mg/m2 intravenous gemcitabine on day 1 and day 8

  • 70 mg/m2 intravenous cisplatin (split into 2 doses on day 1 and day 8)

06

What researchers measure

Primary outcomes

  1. the radiational disease-free survival (rDFS)

    Time frame: 1 year

Secondary outcomes

  1. Progression Free Survival (PFS)

    time to recurrence

    Time frame: 1 year

  2. Overall Survival (OS)

    Time frame: 5 year

  3. ctDNA clearance rate in ctDNA(+) patients

    Time frame: 1 year

07

Study locations

1 site
  • Queen Mary Hospital
    Hong Kong, Hong Kong, Hong Kong
08

References and documents

Publications

  • Zhan Y, Ruan X, Wu Y, Chun TTS, Yao C, Shi R, Liu J, Ali S, Ma R, Huang D, Gao Y, Xu Y, Chen L, Du Q, Ng AT, Li CWB, Xu D, Na R. Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: Protocol for a Pilot Randomized Controlled Trial. JMIR Res Protoc. 2025 Aug 26;14:e72597. doi: 10.2196/72597. PubMed 40857715 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2024 to primary completion in Sep 2025, 19 months.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2025 → Aug 2026, on Oct 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2024
First posted
Feb 13, 2024
StartActual
Feb 2, 2024
Primary completionActual
Sep 30, 2025
CompletionActual
Aug 22, 2026was Dec 2025
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 28, 2026
Sites
1 site added, 1 site removed
Show site
  • Queen Mary Hospital · Hong Kong, Hong Kong
Show 1 removed
  • Queen Mary Hospital · Hong Kong, Hong Kong
Oct 28, 2026
Study completion
Dec 30, 2025→Aug 22, 2026 (actual)
Oct 28, 2026
Enrollment
20 (estimated)→15 (actual)
Oct 28, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40857715 ↗
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40857715 ↗
    1 site added, 1 site removed
    Show site
    • Queen Mary Hospital · Hong Kong, Hong Kong
    Show 1 removed
    • Queen Mary Hospital · Hong Kong, Hong Kong
    Study completion Dec 30, 2025→Aug 22, 2026 (now actual)
    Enrollment 20 (estimated)→15 (actual)
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06257017
Lead sponsor
Yung NA
Collaborators
Pamela Youde Nethersole Eastern Hospital, Queen Mary Hospital, Hong Kong
Responsible party
Yung NA (Clinical Assistant Professor, The University of Hong Kong) — Sponsor-investigator
First posted
Feb 13, 2024
Start date
Feb 2, 2024
Primary completion
Sep 30, 2025
Completion
Aug 22, 2026
Last update
Oct 28, 2026

Study contacts

Yung Na, PHD
principal investigator · The University of Hong Kong

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemcitabine · Cisplatin

Start the discussion